Gene therapy for neuroprotection
AssigneeThe Regents of the University of California
InventorsDerek S. WELSBIE, Mai T. VU, Cassidy D. LEE, Amit K. PATEL
Life of this patent
Estimating the term…
Abstract
Provided herein, inter alia, are methods and compounds for treating and preventing neural cell death, e.g., retinal ganglion cell death. Also provided herein, inter alia, are methods and compounds for treating and preventing nerve degeneration. The methods and compounds provided herein may treat or prevent glaucoma.
Claims45
A nucleic acid encoding a dominant negative Dual Leucine Zipper Kinase (dnDLK) polypeptide comprising an amino acid segment with a sequence having at least 80% identity to region 1-520 of SEQ ID NO:1, wherein the dnDLK polypeptide comprises at least one mutation, as determined with reference to SEQ ID NO:1, wherein the mutation is a substitution at position 302, wherein the substitution is any amino acid other than threonine.
An isolated nucleic acid encoding a leucine zipper polypeptide that inhibits homodimerization and DLK heterodimerization with (LZK), wherein the polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO:8;
- or comprises SEQ ID NO:8.
An isolated nucleic acid encoding a dominant negative dual leucine zipper (dnDLK) polypeptide comprising an amino acid sequence having at least 90% identity to region 158-520 of SEQ ID NO:1, wherein the polypeptide comprises at least one mutation, as determined with reference to SEQ ID NO:1, wherein the at least one mutation is at position 302.
Dependencies are inferred from the claim text.